NewAmsterdam Pharma Company N.V. NAMS

Updated: 13 Sep 2026

NASDAQ | Biotech | Biotechnology and pharmaceutical development

No signal published yet

We already track NewAmsterdam Pharma Company N.V. and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow NewAmsterdam Pharma Company N.V. free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Biotechnology and pharmaceutical development
We're already tracking NewAmsterdam Pharma Company N.V. — here are the latest events we've registered

Recent News

  • On July 24, 2026, NewAmsterdam Pharma announced that the EMA's CHMP issued a positive opinion recommending EU marketing authorization for obicetrapib monotherapy and its fixed-dose combination with ezetimibe. In its second-quarter 2026 financial report released on August 5, 2026, the company reported $678.3 million in cash, cash equivalents, and marketable securities. NewAmsterdam also confirmed that an interim analysis for its pivotal Phase 3 PREVAIL cardiovascular outcomes trial is planned for the fourth quarter of 2026.

What Firelda Watch includes for NewAmsterdam Pharma Company N.V.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of NewAmsterdam Pharma Company N.V. will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Hansa Biopharma AB (publ)
HNSA
HOLD
Bioarctic
BIOA B
BUY
Sprint Bioscience AB (publ)
SPRINT
NEUTRAL
Xbrane Biopharma AB (publ)
XBRANE
HOLD
SynAct Pharma AB
SYNACT
HOLD

Biotech

More companies in this sector

Want to follow NewAmsterdam Pharma Company N.V.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow NewAmsterdam Pharma Company N.V. free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

NewAmsterdam Pharma Company N.V. NAMS
NewAmsterdam Pharma Company N.V. — follow and we'll monitor it
Follow NewAmsterdam Pharma Company N.V. free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.